Myeloma Trial, Recruiting NCT05706766 Sponsor: Dana-Farber Cancer Institute Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT05706766
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People who have been diagnosed with multiple myeloma, referred to the Dana-Farber Cancer Institute (DFCI) transplant team, and placed on the waiting list for their first autologous stem cell transplant
  • People who are planning to receive an autologous stem cell transplant at DFCI in 8 weeks or more, with or without other treatments at the same time
  • People who have been cleared by their treating doctor or a certified clinical exercise specialist to safely do moderate-to-vigorous aerobic and resistance exercise, as well as fitness testing
  • People who speak English
  • People who currently do 60 minutes or less of structured moderate-to-vigorous exercise per week
  • People who are willing and able to travel to DFCI for required data collection visits
  • People who are willing and able to understand and sign a written consent form
  • Women who could become pregnant must agree to take a pregnancy test and use reliable contraception (such as hormonal methods, barrier methods, or abstinence) before joining and for six months after the study ends, and must tell their treating doctor right away if they become pregnant or think they might be pregnant during the study

Who may not be able to join:

  • People with a history of unstable chest pain (angina), an abnormal resting heart test (ECG), or a heart attack within the past month, as these may make certain exercise testing unsafe
  • People with known spinal instability, spinal cord compression, nerve problems, or other conditions that make exercise unsafe
  • People who have had spine surgery or surgery for a bone fracture within the past six weeks
  • People considered unsuitable by the transplant team or study team
  • People whose doctor has determined they are at high risk of a bone fracture in a weight-bearing bone, such as the spine, hip, thigh bone, or upper arm bone
  • People who are unwilling or unable to take part in a regular exercise program
  • People with pre-existing muscle, joint, heart, lung, or metabolic conditions that could be made worse by exercise, or any other condition their doctor considers unsafe for exercise participation
  • People who are currently being treated for another active cancer
  • People who already do more than 60 minutes of structured moderate-to-vigorous exercise per week
  • People who are unable or unwilling to travel to DFCI for required data collection
  • People who, in the opinion of the study investigators, may not be able to follow the study's safety monitoring requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Christina Dieli-Conwright, PhD, MPH, Dana-Farber Cancer Institute

Phone: 617-582-8321

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
29 June 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Difference in Muscular Strength

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov